FIT Biotech Oy
Press Release July 4th, 2018, 12.30 EET
FIT Biotech’s company site has been launched in Inderes.fi
FIT Biotech’s company site has been launched at the Inderes.fi-service: https://www.inderes.fi/yhtiot/fit-biotech
The purpose of the site is to offer investors current and up-to-date information about the company in one place. In the future, the site will be updated with company presentations, financial reports and executive interviews.
“Our goal is to have an open and increasingly more diverse dialogue with our investors and we believe that Inderes.fi is an excellent channel for reaching private investors. We want to be available, and Inderes.fi provides us an excellent way to accomplish that”, comments FIT Biotech CEO Erkki Pekkarinen.
Additional information:
CEO Erkki Pekkarinen
Phone +358 44 027 0080
email: erkki.pekkarinen@fitbiotech.com
About FIT Biotech
FIT Biotech Oy is a biotechnology company established in 1995. The company develops and licenses its patented GTU® (Gene Transport Unit) vector technology for new-generation medical treatments. GTU® is a gene transport technology that meets an important medical challenge in the usability of gene therapy and DNA vaccines.
FIT Biotech applies GTU® technology in its drug development programmes. Application areas include cancer (gene therapy) and infectious diseases.
FIT Biotech shares are listed on the First North Finland marketplace maintained by Nasdaq Helsinki Oy.
DISTRIBUTION:
Principal media
www.fitbiotech.fi
